Disease Landscape and Forecast Insights

Gastric cancer is the fourth-most common malignancy in terms of incidence and is the third-most common cause of cancer-related death worldwide. Japan has the highest incidence of gastric cancer…

Last Updated 16 September 2014 Owing to its large population, the treatment of breast cancer remains an active area of research with a rich and diverse product pipeline. A competitive current…

The number of diagnosed acute heart failure (AHF) events and prevalent chronic heart failure (CHF) cases in the seven major markets that we cover is increasing annually, driven by changes in the…

Last Updated 12 September 2014 The type 2 diabetes therapy market will rapidly expand over our 2013-2023 study period, fueled by the disease’s increasing prevalence and a high unmet need for…

Gram-negative infections (GNIs) represent a high-value segment of the antibiotic market and are often treated in the hospital setting. Infections due to Gram-negative pathogens (GNPs) are…

Crohn’s disease (CD) and ulcerative colitis (UC) are two gastrointestinal autoimmune/inflammatory indications that commonly feature treatment with biological therapies. The U.S. CD market…

South Korea and Taiwan have the most advanced healthcare systems among Asian countries, and both operate a universal health insurance program that covers inpatient and outpatient services as well…

Pulmonary hypertension (PH) is a devastating disease, for which there is no cure. Despite the rarity of the disease, the potential commercial rewards from drugs approved for it are considerable,…

In 2013, global sales of ethical oncology drugs exceeded $92 million, and sales are expected to exceed $120 million in 2020, far more than the drug revenues of any other therapy area. Thus,…

With approximately two-thirds of peripheral arterial disease (PAD) patients being asymptomatic, drug treatment for PAD patients focuses largely on the symptomatic patients who have either…

The TreatmentTrends: Rheumatoid Arthritis 2014 (EU) report explores the treatment dynamics among more than 200 French, German, Italian, Spanish, and UK rheumatologists through comprehensive primary…

The type 2 diabetes (T2D) therapy market in Latin America (LatAm) presents a large commercial opportunity to drug manufacturers. The prevalence of T2D in LatAm is high and is expected to increase,…